NEW YORK, Nov. 2 (GenomeWeb News) - Beckman Coulter will provide Consorta its chemistry, immunoassay, hematology, and automation product lines, the company said today.
The three contracts are worth approximately $105 million over the next five years to Beckman. Consorta also extended its hematology agreement with Beckman, valued at $10 million a year, for two more years, Beckman said.
The contract provisions include the company's new line of UniCel systems, such as the DxC 600 and 800 chemistry analyzers, the DxI 800 Access immunoassay system, and the Power Processor automation system, said Robert Kleinert, an executive vice-president at Beckman Coulter, in a statement.
Consorta will also have access to nearly 200 different reagent kits.